BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24786585)

  • 1. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
    J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Krishnaiah M; Jin CH; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 1-(6-methylpyridin-2-yl)-5-(quinoxalin-6-yl)-1,2,3-triazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Li F; Park Y; Hah JM; Ryu JS
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1083-6. PubMed ID: 23294702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
    Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
    Son JY; Park SY; Kim SJ; Lee SJ; Park SA; Kim MJ; Kim SW; Kim DK; Nam JS; Sheen YY
    Mol Cancer Ther; 2014 Jul; 13(7):1704-16. PubMed ID: 24817629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
    Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
    Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jung SH; Lee HS; Dewang PM
    Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Krishnaiah M; Jin CH; Sreenu D; Subrahmanyam VB; Rao KS; Son DH; Park HJ; Kim SW; Sheen YY; Kim DK
    Eur J Med Chem; 2012 Nov; 57():74-84. PubMed ID: 23047226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
    Park CY; Kim DK; Sheen YY
    Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of N-(3-fluorobenzyl)-4-(1-(methyl-d
    Kang BN; Kang HJ; Kim S; Lee J; Lee J; Jeong HJ; Jeon S; Shin Y; Yoon C; Han C; Seo J; Yun J
    Bioorg Med Chem Lett; 2023 Apr; 85():129205. PubMed ID: 36858078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
    Kim YW; Kim YK; Lee JY; Chang KT; Lee HJ; Kim DK; Sheen YY
    Xenobiotica; 2008 Mar; 38(3):325-39. PubMed ID: 18274960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
    Kim DK; Choi JH; An YJ; Lee HS
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
    Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1
    Park MS; Park HJ; An YJ; Choi JH; Cha G; Lee HJ; Park SJ; Dewang PM; Kim DK
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):702-712. PubMed ID: 32164459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
    Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
    Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.